AR128130A2 - Métodos para evaluar conveniencia de un filtro bioquímico - Google Patents
Métodos para evaluar conveniencia de un filtro bioquímicoInfo
- Publication number
- AR128130A2 AR128130A2 ARP220103612A ARP220103612A AR128130A2 AR 128130 A2 AR128130 A2 AR 128130A2 AR P220103612 A ARP220103612 A AR P220103612A AR P220103612 A ARP220103612 A AR P220103612A AR 128130 A2 AR128130 A2 AR 128130A2
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- filters
- biochemical filter
- evaluate suitability
- endotoxins
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002158 endotoxin Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000004886 process control Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D24/00—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof
- B01D24/02—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration
- B01D24/10—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration the filtering material being held in a closed container
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
- C12M37/02—Filters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Realizaciones de la presente revelación incluyen métodos y sistemas para detectar la presencia de endotoxinas en filtros. Por ejemplo, realizaciones de la presente revelación se dirigen a métodos y sistemas para mejorar controles en procesos mediante detección de cantidades no deseadas de endotoxinas en filtros que contienen materiales que provienen de fuentes que se dan naturalmente previo a usar aquellos filtros en la producción de sustancias farmacéuticas formuladas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862665721P | 2018-05-02 | 2018-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128130A2 true AR128130A2 (es) | 2024-03-27 |
Family
ID=67106126
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101127A AR114848A1 (es) | 2018-05-02 | 2019-04-29 | Métodos para evaluar conveniencia de un filtro bioquímico |
ARP220103612A AR128130A2 (es) | 2018-05-02 | 2022-12-27 | Métodos para evaluar conveniencia de un filtro bioquímico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101127A AR114848A1 (es) | 2018-05-02 | 2019-04-29 | Métodos para evaluar conveniencia de un filtro bioquímico |
Country Status (7)
Country | Link |
---|---|
US (2) | US11378571B2 (es) |
EP (1) | EP3787766A1 (es) |
CN (2) | CN116212464A (es) |
AR (2) | AR114848A1 (es) |
CA (1) | CA3097903A1 (es) |
TW (2) | TW202348297A (es) |
WO (1) | WO2019212881A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114602237B (zh) * | 2022-03-10 | 2023-11-28 | 华兰生物工程股份有限公司 | 一种从人血浆或人血浆衍生原料中去除内毒素的方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM388494A0 (en) | 1994-02-16 | 1994-03-10 | Csl Limited | Process for removing endotoxins |
DE69623196T3 (de) * | 1995-06-30 | 2019-11-21 | Toray Industries, Inc. | Permselektive Membranen und Verfahren zu ihrer Herstellung |
US6953686B1 (en) * | 1999-05-28 | 2005-10-11 | Cambrex Bio Science Baltimore, Inc. | Methods of DNA purification and purified DNA |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7083987B2 (en) * | 2001-02-05 | 2006-08-01 | Activx Biosciences, Inc. | Activity based probe analysis |
US6942802B2 (en) * | 2001-04-13 | 2005-09-13 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
WO2003002731A1 (en) * | 2001-06-29 | 2003-01-09 | Hemebiotech A/S | A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD) |
FR2840992B1 (fr) * | 2002-06-18 | 2004-09-03 | Hemosystem | Procede de denombrement et/ou d'identification morphologique de leucocytes en phase solide |
CA2621047A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
US20110159130A1 (en) * | 2007-02-28 | 2011-06-30 | Sanjay Jain | Reduction of endotoxin in polysialic acids |
WO2008148010A1 (en) * | 2007-05-23 | 2008-12-04 | Vgx Pharmaceuticals, Inc. | Composition comprising high concentration of biologically active molecules and processes for preparing the same |
DE102008037678A1 (de) * | 2008-08-14 | 2010-02-25 | Sartorius Stedim Biotech Gmbh | Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid |
LT2848625T (lt) * | 2008-08-14 | 2019-10-10 | Genentech, Inc. | Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba |
US8277649B2 (en) | 2009-12-14 | 2012-10-02 | General Electric Company | Membranes and associated methods for purification of antibodies |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
US8941405B2 (en) | 2012-08-03 | 2015-01-27 | International Business Machines Corporation | FET pair based physically unclonable function (PUF) circuit with a constant common mode voltage |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
KR20160013173A (ko) | 2013-08-30 | 2016-02-03 | 이엠디 밀리포어 코포레이션 | 추출가능물이 적은 대용량 복합 심층 필터 매질 |
JP2017536391A (ja) | 2014-12-02 | 2017-12-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−6rアンタゴニストを投与することによってドライアイ疾患を治療するための方法 |
CN105251049B (zh) | 2015-09-29 | 2018-04-10 | 浙江星月生物科技股份有限公司 | 一种去除生物医用材料中细菌内毒素的离子缓冲液及应用 |
-
2019
- 2019-04-17 TW TW112131975A patent/TW202348297A/zh unknown
- 2019-04-17 TW TW108113294A patent/TWI814812B/zh active
- 2019-04-26 CN CN202310153482.3A patent/CN116212464A/zh active Pending
- 2019-04-26 CA CA3097903A patent/CA3097903A1/en active Pending
- 2019-04-26 CN CN201980028426.9A patent/CN112020384B/zh active Active
- 2019-04-26 US US16/395,431 patent/US11378571B2/en active Active
- 2019-04-26 WO PCT/US2019/029268 patent/WO2019212881A1/en unknown
- 2019-04-26 EP EP19734173.8A patent/EP3787766A1/en active Pending
- 2019-04-29 AR ARP190101127A patent/AR114848A1/es active IP Right Grant
-
2022
- 2022-05-26 US US17/804,222 patent/US20220404335A1/en active Pending
- 2022-12-27 AR ARP220103612A patent/AR128130A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202348297A (zh) | 2023-12-16 |
EP3787766A1 (en) | 2021-03-10 |
US20190339254A1 (en) | 2019-11-07 |
CN112020384A (zh) | 2020-12-01 |
CN112020384B (zh) | 2023-03-10 |
TW201946687A (zh) | 2019-12-16 |
US20220404335A1 (en) | 2022-12-22 |
AR114848A1 (es) | 2020-10-21 |
TWI814812B (zh) | 2023-09-11 |
CN116212464A (zh) | 2023-06-06 |
CA3097903A1 (en) | 2019-11-07 |
WO2019212881A1 (en) | 2019-11-07 |
US11378571B2 (en) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691364A1 (ru) | Способ превращения смеси пластмассовых отходов (mwp) в ценные нефтехимические продукты | |
BR112018003326A2 (pt) | anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos | |
BR112017001212A2 (pt) | processamento de biomassa | |
CL2019001517A1 (es) | Anticuerpos y métodos de su utilización. | |
CO2018000244A2 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
AR128130A2 (es) | Métodos para evaluar conveniencia de un filtro bioquímico | |
CU20150104A7 (es) | Método de separación de sólidos de líquidos de un lodo que comprende biomasa | |
MX2017007766A (es) | Material no tejido, metodo para fabricar el mismo y articulos que incorporan el material no tejido. | |
BR112017026558B8 (pt) | Cartucho para a separação de uma mistura de fluidos, módulo de separação de fluidos e método para a separação de uma mistura composta por pelo menos dois fluidos | |
EA201692157A1 (ru) | Синтез двухцепочечных нуклеиновых кислот | |
MX2021009746A (es) | Materiales polimericos de ciclodextrina con carga y metodos para su fabricacion y uso. | |
AR119393A1 (es) | Anticuerpos que se unen a nkg2d | |
BR112018067951A2 (pt) | moléculas que se ligam a ilt7 e métodos de uso destas | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
AR104358A1 (es) | Método para la purificación de proteínas | |
EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
PL439807A1 (pl) | Sposoby oczyszczania przeciwciał i ich kompozycje | |
TR201901872T4 (tr) | Kağıt hamuru ve kağıt endüstrisinin yan akışlarını ve atık akışlarını işleme yöntemi ve bir gübre. | |
CO2018010286A2 (es) | Método para la purificación de proteínas | |
ZA202203400B (en) | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis | |
CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
EP4310184A3 (en) | Methods of screening antigen-binding molecules by normalizing for the concentration of antigen-binding molecule | |
BR112021021673A2 (pt) | Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo | |
BR112021012302A8 (pt) | Métodos e produtos para converter dióxido de carbono em um ou mais compostos orgânicos pequenos | |
MX2023007357A (es) | Ensayo de gradiente de difusion para moleculas que contienen anti-cd3. |